In an advanced pancreatic cancer phase 1/1B single-arm clinical trial (212), a regimen combining ADI-PEG20, gemcitabine, and nab-paclitaxel demonstrated tolerability and efficacy in both previously treated and untreated advanced pancreatic cancer patients, including those with ASS1-deficient tumors. This evidence concerns the gene ASS1 and pancreatic neoplasm.